This study aimed to evaluate long-term tumor control, safety, and prognostic factors following single-fraction stereotactic radiosurgery (SRS) for vestibular schwannoma (VS).
Single-fraction SRS appears to provide durable long-term tumor control for vestibular schwannoma, but this is a retrospective single-centre series; audiologists managing post-SRS patients should continue monitoring hearing and balance outcomes per existing protocols rather than changing referral thresholds based on this study alone.
Long-term outcome data on single-fraction SRS for vestibular schwannoma are still limited, and a 10-year retrospective experience adds meaningful prognostic information for multidisciplinary teams counselling patients on treatment options.
- 0110-year retrospective analysis of single-fraction SRS outcomes for vestibular schwannoma.
- 02Primary endpoints likely include tumor control rate, hearing preservation, and facial nerve function.
- 03Prognostic factors identified may guide patient selection for SRS vs. other management strategies.
- 04Retrospective design limits causal inference; no randomised comparator group.
- 05Published in Radiation Oncology Journal (2026); indexed on PubMed (PMID 42392687).
Single-fraction stereotactic radiosurgery achieves durable tumor control in vestibular schwannoma over a 10-year follow-up period.
studypartially supportedSingle-fraction SRS is safe with acceptable rates of hearing and facial nerve preservation over 10 years.
studypartially supported- PMID
- 42392687
- DOI
- 10.3857/roj.2026.00094.
- Journal
- Radiation Oncology Journal
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with vestibular schwannoma treated with single-fraction stereotactic radiosurgery
- Intervention
- Single-fraction stereotactic radiosurgery (SRS) for vestibular schwannoma
Primary outcomes
Long-term tumor control rate; Hearing preservation; Facial nerve function preservation